Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA

Company Update - Exousia Pro has received Orphan Drug Designation (ODD) from the FDA for its exosome-based treatment targeting malignant Glioma, specifically Glioblastoma multiforme (GBM) [1][2] - Only 11% of Orphan Drug Designations are awarded at the preclinical stage, highlighting the significance of this achievement for Exousia Pro [1] Technology and Treatment - The company utilizes breakthrough exosomal technology that can deliver a variety of therapeutics, including genetic material, directly into cancer-afflicted cells [3] - The treatment method involves using exosomes loaded with nucleic acids, which is intended to be combined with existing standard anticancer therapies for effective GBM treatment [3] Market Potential - The company estimates the value of the ODD to be in the tens of millions of dollars and plans to work with investment bankers to monetize this designation as it progresses its therapy [4] - GBM is described as a highly malignant tumor with inadequate treatment options, indicating a significant unmet medical need in this area [3][4] Company Overview - Exousia Pro, Inc. specializes in developing and manufacturing exosomes derived from mammalian and plant sources, utilizing proprietary technologies for targeted delivery [5] - The engineered exosomes are designed to target cancer stem cells, which are crucial in cancer recurrence and metastasis, thereby enhancing patient responsiveness to anticancer therapies [5]